Related Experiment Videos
Receptor-mediated and enzyme-dependent targeting of cytotoxic anticancer drugs
1Bristol-Myers Squibb Pharmaceutical Research Institute, Wallingford, CT 06492-7660, USA. dubowchg@bms.com
Abstract:
This review is a survey of various approaches to targeting cytotoxic anticancer drugs to tumors primarily through biomolecules expressed by cancer cells or associated vasculature and stroma. These include monoclonal antibody immunoconjugates; enzyme prodrug therapies, such as antibody-directed enzyme prodrug therapy, gene-directed enzyme prodrug therapy, and bacterial-directed enzyme prodrug therapy; and metabolism-based therapies that seek to exploit increased tumor expression of, e.g., proteases, low-density lipoprotein receptors, hormones, and adhesion molecules. Following a discussion of factors that positively and negatively affect drug delivery to solid tumors, we concentrate on a mechanistic understanding of selective drug release or generation at the tumor site.
Insights
This review explores targeted cancer drug delivery strategies, focusing on antibody conjugates, enzyme prodrug therapies, and metabolism-based approaches to enhance drug selectivity and efficacy at tumor sites.
Area of Science:
- Oncology
- Pharmacology
- Biotechnology
Background:
- Targeted drug delivery aims to improve cancer treatment efficacy by concentrating cytotoxic agents at tumor sites.
- Conventional chemotherapy faces challenges like systemic toxicity and poor drug penetration into solid tumors.
- Tumor-specific biomolecules offer potential targets for selective drug localization.
Purpose of the Study:
- To survey and analyze diverse strategies for targeting cytotoxic anticancer drugs to tumors.
- To elucidate the mechanisms underlying selective drug release or generation at the tumor site.
- To discuss factors influencing drug delivery to solid tumors.
Main Methods:
- Review of literature on various drug targeting approaches.
- Analysis of antibody-based conjugates and enzyme prodrug therapies (antibody-directed, gene-directed, bacterial-directed).
- Examination of metabolism-based therapies exploiting tumor-specific molecular expression (proteases, receptors, hormones, adhesion molecules).
Main Results:
- Monoclonal antibody immunoconjugates offer specific tumor cell targeting.
- Enzyme prodrug therapies demonstrate potential for localized drug activation.
- Metabolism-based strategies leverage unique tumor metabolic profiles for drug targeting.
Conclusions:
- Targeted drug delivery strategies, including antibody conjugates and enzyme prodrug therapies, show promise for improving cancer treatment.
- Understanding factors affecting drug delivery and tumor-specific molecular expression is crucial for optimizing therapeutic outcomes.
- Further research into selective drug release mechanisms can enhance the efficacy and reduce the toxicity of anticancer therapies.